戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                             To define the natural history of NSE in an Irish cohort.
2                                                             To define the physical basis for EapH1's inhibition of cathep
3                                                             To define the role of ATM loss in prostate tumor DDR function
4                                                             To define the signature, we performed network deconvolution o
5                                                             To define the transcriptional profile of this airway immune d
6 onse and protection in coronavirus disease 2019 (COVID-19), to define previous exposure to severe acute respiratory syndr
7 niaturize, leak electrolyte to the medium, lose the ability to define the electrochemical potential precisely in time, co
8 nd master regulator analysis (MRA) have been widely adopted to define specific transcriptional perturbations from gene ex
9                         In this prospective study, we aimed to define a serum glycomic signature in the first week after
10                                                    We aimed to define cell types in PB and to analyze their relationship
11                                                    We aimed to define prolonged critical illness, delineate between nonmo
12                                             This paper aims to define the concepts of primary pseudotumor cerebri, in whi
13                              Thus, it allows power analyses to define minimally required sample sizes.
14                         We consequently present an approach to define gene interaction networks underlying important cell
15          Two informatics approaches (subtype categorization to define phylogenetic clusters and the development of an SNP
16  2000-2013, employing diagnoses, drugs, and procedure codes to define diseases and procedures.
17                   Heterogeneity characterization is crucial to define the quality of end products and to describe the evo
18 les in regulation of immune cell signaling, current efforts to define its roles in disease processes, and approaches to t
19                     Transposon sequencing has been employed to define the core essential genome of this bacterium and gen
20 NA-sequencing (scRNA-seq) data of gastric corpus epithelium to define transcriptomes of individual epithelial cells from
21          Previously, SWI/SNF chromatin remodeling was found to define the kinetics and selectivity of gene activation in
22  FMF-related AA amyloidosis and glomerulonephropathies (GN) to define possible predictors for CVDEs.
23                                     These results will help to define future strategies for prophylaxis of bleeding in AH
24          We used the apnea-hypopnea index (events per hour) to define obstructive sleep apnea severity (normal, <5.0; mil
25                                       Thus, it is important to define the patient population that would now be considered
26 essive cell commitment, remodeling the epigenomic landscape to define the presumptive neural crest.
27                     We used G-quadruplex-stabilizing ligand to define the inhibition in LANA expression and presentation
28 notypes and the limited predictive value of surface markers to define lineages, functions, or subpopulations.
29 ntific statements recommend multimodality imaging in MINOCA to define the underlying cause.
30                                       Next, we used PET/MRI to define uptake in six brain regions.
31  gene editing and engineered separation-of-function mutants to define how CENP-F contributes to kinetochore function.
32                                  Further research is needed to define the role of asymptomatic hyperuricaemia in these pr
33 ell transcriptome characterization of CF sputum.Objectives: To define the transcriptional profile of sputum cells and its
34  the geometry of decision-making in outlier cells, in order to define evolution-resistant cancer biomarkers.
35 outcome and is applied to disaggregate patients within RCTs to define risk-based variation in benefit, and an "effect-mod
36 hus, our data reveal that -31CBS acts as critical regulator to define +19-enhancer and the leukemic prone promoter IV int
37                            Further studies will be required to define whether inter-individual variations in ABO(H) expre
38 connections of varying step heights are displayed and shown to define both deformed and recovered structures.
39                                                   We sought to define cis-acting elements in the HIV-2 genome that are im
40 omputed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the b
41 t underwent additional PCR- and immunohistochemical testing to define a sensitive ground truth of HP presence.
42  many features of severe COVID-19 infection and can be used to define the basis of lung disease and test immune and antiv
43 esholds and durations (2, 3, and 4 consecutive d) were used to define 15 different heatwaves.
44  (ICD-9) codes or their Tenth Revision equivalent were used to define a diagnosis of OSA (ICD-9 327.23) and a diagnosis o
45 enome sequencing of the pncA, rpsA and panD genes were used to define PZA resistance.
46                                                 Our aim was to define an original workflow for the purification and syste
47                                           Our objective was to define the prevalence and correlates of abnormal pulmonary
48                                  The goal of this study was to define the functions of Bcl6 in Treg cells, including Tfr
49                               The purpose of this study was to define the risk of, and associations with, SAE and high-do
50                          The aims of the present study were to define mechanisms of Treg subpopulation imbalance and iden